DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ectodermal dysplasia syndrome — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEctodermal dysplasia syndrome maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ectodermal dysplasia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ornithine decarboxylase 1 (ODC1) — ODC1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2OO0 · 1.9 Å · ligand PYRIDOXAL-5'-PHOSPHATE (PLP). Experimental structure, not a prediction.
What the evidence adds up to
The four abstracts provided describe ectodermal dysplasia syndrome only as a diagnostic category, not as a target of any drug treatment. A 2014 case report and a 1931 case report simply list the clinical features — sparse hair, missing teeth, inability to sweat, nail defects, and in the 1931 case mental retardation — without any therapeutic intervention. A 2016 case report of odonto-onycho-dermal dysplasia in a patient homozygous for a WNT10A nonsense mutation notes that the skin and nail abnormalities were for many years misinterpreted as psoriasis and treated accordingly, but no drug name, response rate, or survival data are given. The 1997 abstract describes a successful intracytoplasmic sperm injection procedure for a man with dysplasia of the fibrous sheath and dynein deficiency, a condition the authors relate to immotile cilia syndrome; this is a fertility technique, not a drug, and no drug is mentioned.
A 2009 perspective article discusses gene therapy and protein therapy for ectodermal dysplasias in general terms, stating that characterisation of molecular events "opens the door" to such options and provides "a concise overview of the most recent successes and failures," but it gives no concrete numbers — no survival rates, no response rates, no sample sizes — and does not name any specific drug, gene, or protein that was tested. A 2019 review similarly describes advances in molecular genetic testing and the need for multidisciplinary management, but again reports no drug, no trial, and no quantitative outcome.
There is therefore no evidence in these abstracts for any drug that treats ectodermal dysplasia syndrome. What is missing is any clinical trial of a pharmacological agent, any patient stratification by genotype, and any funding for such trials. The abstracts themselves note that the condition is heterogeneous and that molecular classification is still evolving, which means that even if a drug were proposed, it would need to be tested in defined genetic subgroups.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Reproduction · 1997 · 44 citations · open access
Successful intracytoplasmic sperm injection with spermatozoa from a patient with dysplasia of the fibrous sheath and chronic respiratory disease
AbstractThe present report describes a successful intracytoplasmic sperm injection (ICSI) procedure performed with immotile spermatozoa from a young man with a combination of dysplasia of the fibrous sheath and dynein deficiency, a recently described variant of the immotile cilia syndrome. This methodology provides the only suitable solution for these patients in whom all other assisted fertilization technologies have previously failed, and opens the possibilities for treatment of male infertility due to severe, irreversible sperm defects such as the one reported here.
BMC Dermatology · 2016 · 15 citations · open access
Odonto-onycho-dermal dysplasia in a patient homozygous for a WNT10A nonsense mutation and mild manifestations of ectodermal dysplasia in carriers of the mutation
AbstractBACKGROUND: Odonto-onycho-dermal dysplasia (OODD) is a rare form of ectodermal dysplasia characterized by severe oligodontia, onychodysplasia, palmoplantar hyperkeratosis, dry skin, hypotrichosis, and hyperhidrosis of the palms and soles. The ectodermal dysplasias resulting from biallelic mutations in the WNT10A gene result in highly variable phenotypes, ranging from isolated tooth agenesis to OODD and Schöpf-Schulz-Passarge syndrome (SSPS). CASE PRESENTATION: We identified a female patient, with consanguineous parents, who was clinically diagnosed with OODD. Genetic testing showed that she was homozygous for a previously reported pathogenic mutation in the WNT10A gene, c.321C > A, p.Cys107*. The skin and nail abnormalities were for many years interpreted as psoriasis and treated accordingly. A thorough clinical examination revealed hypotrichosis and hyperhidrosis of the soles and dental examination revealed agenesis of permanent teeth except the two maxillary central incisors. Skin biopsies from the hyperkeratotic palms and soles showed the characteristic changes of eccrine syringofibroadenomatosis, which has been described in patients with ectodermal dysplasias. Together with a family history of tooth anomalies, this lead to the clinical suspicion of a hereditary ectodermal dysplasia. CONCLUSION: This case illustrates the challenges of diagnosing ectodermal dysplasia like OODD and highlights the relevance of interdisciplinary cooperation in the diagnosis of rare conditions.
AbstractEctodermal dysplasia (ED) syndrome comprises a large, heterogeneous group of inherited disorders that are defined by primary defects in the development of 2 or more tissues derived from the embryonic ectoderm. The tissues primarily involved are the skin and its appendages (including hair follicles, eccrine glands, sebaceous glands, nails) and teeth. The clinical features include sparse hair, abnormal or missing teeth, and an inability to sweat due to lack of sweat glands. One such case report of ectodermal dysplasia is presented here.
Archives of Pediatrics and Adolescent Medicine · 1931 · 5 citations
HEREDITARY ECTODERMAL DYSPLASIA
AbstractThe following report is that of a case of hereditary ectodermal dysplasia in a boy, 3½ years of age. He presented multiple defects involving tissues that have their origin in the embryonic ectoderm, namely, the hair, the teeth and the nails of the fingers and toes, as well as evidences of mental retardation. We shall not enter into a discussion of the etiology of the disorder or attempt a review of the literature. These aspects are discussed in an excellent paper by Weech,<sup>1</sup>who collected nine cases of hereditary ectodermal dysplasia from the literature and described two others observed by himself. We wish to call attention, however, to two more recent publications on the subject, one by Clouston<sup>2</sup>and another by Smith.<sup>3</sup>In the paper by Smith, a review of the entire subject is given with a summary of the characteristics of fifteen cases, to which number
American Journal of Medical Genetics Part A · 2009 · 3 citations · open access
Gene therapy and protein therapy of ectodermal dysplasias: A perspective
AbstractEctodermal dysplasias (EDs) form a complex and heterogeneous group of diseases currently defined and classified according to their clinical symptoms. The characterization, for several EDs, of the molecular events underlying their development, not only challenges this classification but also opens the door to new therapeutic options such as gene or protein therapy. This article provides a concise overview of the most recent successes and failures of this new type of treatment and sets in perspective how the specificities of given EDs will influence their feasibility in the near future. It makes the case for the need of new classification of EDs that is based on our most recent knowledge of the molecular basis of these diseases.
Harper's Textbook of Pediatric Dermatology · 2019 · 0 citations
Ectodermal Dysplasias
AbstractThe ectodermal dysplasias (EDs) encompass a complex and highly diverse group of heritable disorders that have developmental abnormalities of ectodermal appendages in common. Recent advances in molecular genetic testing have changed the paradigm of classification to correlate with underlying genotypes. EDs can be divided into defects in developmental regulation and epithelial–mesenchymal interaction, and defects in proteins of cytoskeleton or adhesion, which are involved in cell–cell communication as well as structural integrity. Management of EDs is multidisciplinary and specific to the ED involved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
